Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

“Dupilumab appears promising as a steroid-sparing treatment of ADC-induced cutaneous toxicities,” which “are difficult to ...

In NOTUS, dupilumab reduced exacerbations by 34% at 52 weeks in patients with moderate-to-severe COPD and evidence of type 2 inflammation who were already on max­i­mal standard-of-care in­haled ...

TARRYTOWN, N.Y., May 01, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced 24 abstracts on Dupixent ® (dupilumab) clinical data and real-world analyses in ...

"DUPILUMAB- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Chronic Spontaneous Urticaria in 7 Major Markets. A ...

Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. New England Journal of Medicine, 2021; 385 (24): 2230 DOI: 10.1056/NEJMoa2106567 ...

Between dupilumab, benralizumab and mepolizumab, patients with difficult-to-control asthma had the lowest rate of exacerbations in the first year of dupilumab, according to results published in ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut allergy was not achieved, according to results published in Allergy.“The ...

There is no established standard care for prurigo nodularis. The clinical expert explained that while treatment between centres varies, it usually follows a 'stepped approach'. This is when treatments ...